SCHEMBL17433339

SCHEMBL17433339

CN1CCN(c2ccc3nc(-c4c(N)c5ccccc5[nH]c4=O)[nH]c3c2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 19/20 1.00
PDGFRB P09619 17/20 1.00
KDR P35968 17/20 1.00
FLT1 P17948 5/20 1.00
LCK P06239 2/20 0.73
PLK4 O00444 1/20 0.73
STK25 O00506 1/20 0.73
CIT O14578 1/20 0.73
RIOK3 O14730 1/20 0.73
CHEK1 O14757 1/20 0.73
GAK O14976 1/20 0.73
CHUK O15111 1/20 0.73
MUSK O15146 1/20 0.73
EPHB6 O15197 1/20 0.73
PDPK1 O15530 1/20 0.73
MAP3K13 O43283 1/20 0.73
DAPK3 O43293 1/20 0.73
MAP3K7 O43318 1/20 0.73
NUAK1 O60285 1/20 0.73
PIP5K1C O60331 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3381227 0.92 FGFR1 (0.85) FGFR1PDGFRBKDRFLT1
SCHEMBL14795687 0.92 FGFR1 (0.84) FGFR1PDGFRBKDRFLT1LCK
SCHEMBL3381059 0.90 FGFR1 (1.00) FGFR1PDGFRBKDRFLT1LCK
SCHEMBL3381351 0.89 FGFR1 (0.81) FGFR1PDGFRBKDRFLT1LCK
SCHEMBL14795663 0.89 FGFR1 (1.00) FGFR1PDGFRBKDRFLT1LCK
SCHEMBL15910869 0.89 FGFR1 (0.81) FGFR1PDGFRBKDRFLT1CHEK1
SCHEMBL3380086 0.89 FGFR1 (0.81) FGFR1PDGFRBKDRFLT1CHEK1
SCHEMBL3384403 0.89 FGFR1 (1.00) FGFR1PDGFRBKDRFLT1CHEK1
SCHEMBL3379764 0.89 FGFR1 (0.79) FGFR1PDGFRBKDRFLT1
SCHEMBL3381338 0.89 FGFR1 (0.86) FGFR1PDGFRBKDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11230589-B2 Fusion molecules and uses thereof FOUNDATION MEDICINE, INC. (US) 2022-01-25 US disclosed
US-20160009785-A1 NOVEL FUSION MOLECULES AND USES THEREOF FOUNDATION MEDICINE, INC. 2016-01-14 US disclosed
US-20160009785-A1 NOVEL FUSION MOLECULES AND USES THEREOF FOUNDATION MEDICINE, INC. 2016-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230589-B2 Fusion molecules and uses thereof RPS27A, CD2BP2, FGB FGFR1 933/4885PDGFRB 234/4885KDR 1552/4885
US-20160009785-A1 NOVEL FUSION MOLECULES AND USES THEREOF RPS27A, CD2BP2, FGB FGFR1 849/4885PDGFRB 254/4885KDR 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.